检索临床试验

NT-112的I期研究, an autologous T-cell therapy product genetically engineered to express an HLA-C*08:02-restricted T cell receptor (TCR), 靶向KRAS G12D突变实体瘤.

未来的, 多中心, 开放标签, non-随机 clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, 包括肝细胞癌, 胆管癌, 胃, 胰腺癌和大肠癌. The [18F]FAPI-74 PET scan will be acquired in patients with proven GI cancers after initial staging using institutional standard methods. The PET scan results will be compared to FAP immunohistochemistry (as the primary objective) and histopathology (as the secondary objective) of the biopsied or resected tissues.

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, 法尼基转移酶抑制剂(FTI), 作为单一疗法和联合疗法, 成年晚期实体瘤患者.

This is a prospective observational 多中心 pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, 旧金山(UCSF)

This study will test the safety of a drug called SGN-EGFRd2 in participants with advanced solid tumors. 它还将研究这种药物的副作用. A side effect is anything a drug does to the body besides treating the disease.

Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic).

本研究将分为三个部分. Parts A and B of the study will find out how much SGN-EGFRd2 should be given to participants. Part C will use the dose found in parts A and B to find out how safe SGN-EGFRd2 is and if it works to treat solid tumor cancers.

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5 -氟尿嘧啶(研究者用), 伊立替康, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.

The purpose of this study is to evaluate the safety and 耐受性 of RO7496353 when administered in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or metastatic solid tumors such as 非小细胞肺癌(NSCLC), 胃 cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). The study will be conducted in 2 stages: an initial safety run-in stage and an expansion stage.

The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.

这项首次人体研究将评估安全性, 耐受性, 药物动力学, and antitumor activity of TORL-3-600 in patients with advanced cancer

This study will test the safety of a drug called SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. 它还将研究这种药物的副作用. A side effect is anything a drug does to the body besides treating the disease.

本研究将分为三个部分. Parts A and B of the study will find out how much SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if SGN-BB228 is safe and if it works to treat solid tumor cancers.

这项临床试验的目的是测试CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.

它旨在回答的主要问题是:

• To assess the safety and 耐受性 of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A)
• To assess the safety and 耐受性 of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and potentially other tumor types (Part B)
• To evaluate how quickly CPO301 is metabolized by the body (药物动力学 or PK)
• To evaluate if antibodies to the study drug develop (immunogenicity)
• 评价药物的初步疗效
• To correlate preliminary efficacy with mutations in a biomarker called EGFR

参与者将:

• 提供书面知情同意
• Undergo screening tests to ensure they are eligible for study treatment
• Attend all required study visits and receive CPO301 by intravenous injection every 3 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment
• Be followed for progression every 3 months for up to 2 years

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• 如果您需要临床试验方面的帮助.gov registration for an oncology study, please contact the Jonsson Comprehensive 癌症中心's Office of Regulatory Compliance.
• 如果您需要临床试验方面的帮助.gov registration for a non-oncology study, please contact the 监管事务办公室.

NT-175的I期研究, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), 靶向TP53 R175H突变体实体瘤.

这项研究正在研究一种新的化合物, AZD8205, as a possible treatment for advanced or metastatic solid tumours

本研究的目的是测试A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), 胰腺癌(PANC), 非小细胞肺癌(NSCLC), and other solid tumors that express CEA and have lost HLA-A*02 expression.

本研究旨在回答的主要问题是:

• Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patients
• Phase 2: Does the recommended dose of A2B530 kill the solid tumor cells and protect the patient's healthy cells

Participants will be required to perform study procedures and assessments, and will also receive the following study treatments:

• BASECAMP-1 (NCT04981119)的入组和分离
• 预处理淋巴细胞耗竭(PCLD)方案
• A2B530 Tmod CAR - T细胞在指定剂量

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and 耐受性 of DB-1305/BNT325 in subjects with advanced solid tumors.

The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. 主要研究目标有:

• to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part)
• to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible reappearance of the tumor (second part)

参加者将获得:

i) a therapeutic protein vaccine ATP150 or ATP 152 ii) a viral vector VSV-GP154 iii) an immune checkpoint inhibitor Ezabenlimab In the second part of the study, researchers will compare treatment group versus observational group.